Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06552169Phase 2Recruiting

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Role: collaborator

NCT05027581Phase 2Completed

Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)

Role: lead

NCT05724576Phase 1Recruiting

Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients

Role: lead

NCT02336646Phase 1Completed

Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

Role: lead

All 4 trials loaded